Common GBA Variants in Parkinson\u27s Disease and Lewy Body Dementia Patients by Mazak, Megan T. et al.
Common GBA Variants in Parkinson’s Disease and Lewy 
Body Dementia Patients
Megan T. Mazak1, Ronald L. Walton, BSc2, Alexandra I. Soto, MS3, Zbidniew K. Wszolek, MD4, Dennis W. Dickson, MD5, Owen A. Ross, PhD6
Department of Neuroscience, Department of Neurology
Mayo Clinic, Jacksonville, FL
Figure 2: Overlapping Symptoms of PD and LBD
Table 1: Demographics of GBA Carrying Patients
Table 2: Genotypic Results of E365K and T408M
•The only significant associations were 
found between the E365K variant and 
the LBD series and LBD high group. 
The LBD high group is the driving force 
for the significance of the LBD series.  
This may be because GBA causes a 
more severe disease and therefore 
resulting in a LBD high pathology.
•GBA is a risk modifier for PD and is not 
causative.  Numbers could be even 
higher if sporadic PD was included, as 
only familial exomes were used.  
•GBA has a stronger effect size in LBD 
than PD as reflected in Table 2.
Conclusions and Future 
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Parkinson’s disease (PD) and Lewy Body Dementias 
(LBD) are two distinct synucleinopathies with a great 
amount of symptomatic and genetic overlap.  This 
overlap can often lead to misdiagnosis.  Misdiagnosis 
can result in improper therapy and therefore a poorer 
prognosis.  LBD is a neuropath diagnosis with 
subcategories, but for the purpose of this project we 
discuss LBD as a whole.  GBA is a gene common to 
both diseases with different effect sizes in each, 
although increasing severity of disease for both.  
Common is defined as a presence greater than 1% in 
healthy controls.  GBA is found in 2-37% of Parkinson 
cases worldwide, with Ashkenazi Jews having the 
highest frequency of mutation.  Our PD cohort is a 
clinical series, whereas our LBD cohort is a pathological 
series.  A clinical LBD series can skew results as they 
are often misdiagnosed, so there is more certainty 
behind a pathological series.  Here, we screened ~200 
samples for E365K and T408M, two common GBA
variants.  We have reviewed the clinical implications of 
being a GBA carrier for both diseases and have 
identified differences.  We have genotyped ~1200 LBD 
samples for these two common variants.  Now that we 
know GBA plays a role in each disease, we can better 
understand the mechanism of pathogenesis and can 
identify potential therapy targets for GBA carriers.  
These therapeutic targets could be a gateway to cures 
and therapies for an otherwise incurable condition.
Abstract
PD Samples
Two tubes of blood samples are collected per patient.  5 mL of each 
sample is transferred to Autogen FlexSTAR sample tubes.  The samples 
are placed in the Autogen FlexSTAR and a simple whole blood DNA 
extraction is performed.  The samples are transferred to 1.5 mL tubes and 
the concentrations of the samples are recorded in ng/µL using the 
NanoDrop 2000.  The DNA is plated at 20µL per sample and is diluted to 
50 ng/µL.  A 5µL Taqman PCR is run using primers for each variant.  
Genotypic results are analyzed using QuantStudio™ 12K Flex Real-Time 
PCR System with OpenArray® Block.
LBD Samples
Brain samples from the brain bank that are LBD confirmed are chipped.  
Two samples are cut per brain and placed in 1.5 mL tubes.  Reagents 
from the QIAamp Fast DNA Tissue Kit are used to digest the tissue.  The 
samples are then placed on a heat block at 55°C until tissues reach full 
digestion.  The samples are then placed in the Autogen FlexSTAR and a 
tissue DNA extraction is performed.  The DNA is then prepped for 
genotypic analysis the same as the blood samples 
Methods
Figure 1: GBA Proposed Mechanism
Figure 1. GBA codes for a lysosomal storage enzyme known as GCase.  Mutant GCase results in aggregation of α-synuclein, 
the primary component of the Lewy bodies that result in these diseases.  Normal GCase leaves the ER and enters a lysosome.  
The lysosome is functional and produces α-synuclein monomers.  Mutant GCase leaves the ER and enters a lysosome.  The 
lysosome is dysfunctional and the α-synuclein monomers begin to oligomerize and aggregate.  Some mutant GCase is 
degraded.  Exact mechanism of aggregation is unknown.
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LBD Series 1298 39% 78.6±8.9








LBD Low 358 
(27.6%)
47% 79.7±10.3
Familial PD 455 41% 68.1±12.6
Controls 885 51% 57.5±15.2
Figure 2.  Many symptoms of PD and LBD overlap.  To be diagnosed with 
LBD, the three LBD symptoms are required along with one of the 
overlapping symptoms.   
Barkhuizen 2016
GBA E365K LBD Series LBD High LBD Inter. LBD Low Fam. PD Controls
Wild Type 1178 492 360 326 436 863
Heterozygous 72 41 15 16 19 22
Homozygous 4 2 1 1 0 0
Total 1254 535 376 343 455 885
MAF 3.190% 4.206% 2.261% 2.624% 2.088% 1.243%
Call Rate 99.2% 99.8% 99.2% 98.3% 100% 100%
OR [95%CI] 2.66 [1.66-4.29] 3.59 [2.14-6.01] 1.85 [0.98-3.51] 2.17 [1.15-4.06] 3.42 [2.01-5.82]
p-value 1.30E-05 4.33E-07 0.064 0.019 0.093
GBA T408M LBD Series LBD High LBD Inter. LBD Low Fam. PD Controls
Wild Type 1217 518 365 334 444 869
Heterozygous 30 12 12 6 11 16
Homozygous 1 1 0 0 0 0
Total 1248 531 377 340 455 885
MAF 1.282% 1.318% 1.592% 0.882% 1.209% 0.904%
Call Rate 98.7% 99.1% 99.5% 97.4% 100% 100%
OR [95%CI] 1.43 [0.78-2.61] 1.47 [0.71-3.02] 1.79 [0.84-3.79] 0.98 [0.38-2.50] 1.35 [0.62-2.91]
p-value 0.239 0.300 0.139 0.959 0.456
